Novartis v Hospira — what do innovators and generics need to know?
In a robust decision handed down by the English Court of Appeal, Novartis has been awarded an interim injunction against Hospira to prevent sales of generic zoledronic acid in the UK despite Novartis’s patents having been declared invalid by the English High Court.
The revocation proceedings are expected to reach the Court of Appeal some time in autumn 2013. Until then, Novartis is able to enjoy market exclusivity on its proprietary zoledronic acid product, Aclasta.
The Court of Appeal judgment represents a significant victory for Novartis and other innovators. In this e-alert, Allen & Overy discusses how this decision affects innovators and generic companies alike, as well as the practical steps that parties should consider prior to the launch of a generic product…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
Sylvia Kierszenbaum and Willem Van de Wiele have authored an article in The International Capital Markets Review.
The Provincial Court of Madrid has upheld a hybrid dispute resolution clause. The judgment is the first one in Spain that recognises the validity of hybrid arbitration clauses.
Analysis from The Lawyer
Advisers get stuck into the disentangling task, to unhitch troubled bank from group
Shell legal director Peter Rees is switching litigation control away from external counsel to a unified global team of in-housers